DMD and muscular dystrophy: Genetically modified [82] or patient-derived primary and immortalised lines have been used to model several muscular dystrophies [74, 91–93] and in the field of personalised medicine, they have shown promise as a tool for disease modelling and drug screening: for example, evaluating the efficacy of antisense oligonucleotide exon-skipping and CRISPR/Cas9 genome editing strategies for DMD [94, 95].